Scientists have developed a promising experimental drug that may help slow the progression of amyotrophic lateral sclerosis (ALS) by protecting nerve cells from damage. In a new study, researchers identified a small harmful region within the TDP-43 protein, which forms toxic clumps in nearly all ALS cases. The experimental drug, XL20, targets this region without disrupting the protein’s normal function. In mouse models, XL20 improved survival, reduced muscle weakness, and protected nerve cells. It also reversed key signs of damage in human motor neurons grown in the lab. While more research and clinical trials are needed, this discovery could pave the way for new treatments for ALS and other TDP-43-related neurodegenerative diseases.
Read more at MedicalXpress